Clinical experience with apremilast for psoriatic arthritis
The novel targeted synthetic disease-modifying antirheumatic drug apremilast (AP), a phosphodiesterase 4 inhibitor, is currently used to treat psoriasis and psoriatic arthritis (PsA). AP treatment can reduce the level of proinflammatory cytokines and the activity of inflammatory changes. The article...
Main Authors: | E. Yu. Loginova, T. V. Korotaeva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2018-09-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/850 |
Similar Items
-
Apremilast: target synthetic drug for the treatment of psoriatic arthritis and psoriasis
by: Yu. L. Korsakova, et al.
Published: (2018-07-01) -
The efficacy and safety of apremilast in patients with psoriatic arthritis concurrent with comorbidity in clinical practice
by: E. Yu. Loginova, et al.
Published: (2019-07-01) -
Phosphodiesterase-4 inhibitor in the treatment of psoriasis and psoriatic arthritis
by: O. Yu. Olisova, et al.
Published: (2019-07-01) -
Apremilast: A dermatologic perspective
by: Aditya Kumar Bubna
Published: (2016-01-01) -
New opportunities in the treatment of psoriasis and psoriatic arthritis
by: A. A. Kubanov, et al.
Published: (2019-01-01)